Lupus Nephritis
Conditions
Keywords
Lupus Nephritis, immunosuppressive agents, Mycophenolic acid, Cyclophosphamide, healthcare costs, cost saving regimen, resource-limited setting, Egypt.
Brief summary
The aim of this study is to conduct a pharmacoeconomic analysis to compare the use of Mycophenolate Mofetil or i.v. Cyclophosphamide as induction therapy from a third party payer perspective in LN patients in the Egyptian context
Sponsors
Nada Magdy Mansour
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Inclusion criteria
\- LN patients between 18 and 65 years of age who were followed up in the Department of Rheumatology and Rehabilitation were included during the study period. All patients fulfilled at least 4 of the 11 American College of Rheumatology (ACR) revised criteria for the classification of SLE 21. Patients were included if they had active lupus nephritis LN(LN) that was confirmed by Class III, or Class IV, or Class V renal biopsy and which was performed within six months of enrolment. Furthermore, laboratory tests must show active nephritis demonstrated by a clinically significant high level of proteinuria, which might indicate a recent decline in renal function 22. Patients with class III or V LN must have either proteinuria (≥ 2 gm/day) or serum creatinine \> 1.3 mg/dl. Patients with class IV must have either proteinuria ≥ 1 gm/day or serum creatinine \> 1.3 mg/dl 23. Newly diagnosed patients who were given either IV CYC or oral MMF as induction therapy or patients who needed to be induced when flared up were included in the study. All patients signed a written informed consent form. For those below the age of 21, written informed consent was obtained from the parents.
Exclusion criteria
* Patients were excluded from the study if they had a history of known allergy to study drugs, received previous kidney transplantation, or were on continuous dialysis for more than two weeks before the study. Patients with combinations of membranous and proliferative glomerulonephritis (i.e., class III + V or class IV + V) renal biopsies were not included. Other reasons for exclusion were pregnancy and lactation, pancreatitis, current infection episode requiring IV antibiotics, severe viral infection, history of cancer, or overlapping autoimmune condition.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| clinical outcomes | 6 months - 12 months | renal remission |
| pharmacoeconomic outcomes | 12 months | comparison of Direct medical costs between both regimens |
| Quality of life outcomes | baseline and after 12 months | SF36 Survey comparison between both groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | 12 months | percentage of adverse events in each group |
Countries
Egypt
Outcome results
None listed